Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Amgen's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of Kyowa Kirin's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Kyowa Kirin, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema)....
Rocatinlimab by Kyowa Kirin for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to...
Rocatinlimab by Kyowa Kirin for Asthma: Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase II for Asthma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Amgen's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...